More recently, biologic anti‐IL‐1 agents, including anakinra and rilonacept, have revolutionized the management of colchicine‐refractory FMF and 3 other monogenic SAIDs: cryopyrin‐associated periodic syndrome (CAPS), TNF receptor–associated periodic syndrome (TRAPS), and mevalonate kinase deficiency (MKD).6, 8. This evidence concerns the gene IL1B and familial Mediterranean fever.